NCT07728721尚未招募2 期
A Randomised, Double-blind, Placebo-controlled Parallel Group Phase II Clinical Study Evaluating the Efficacy and Safety of HSK50042 in Subjects With Idiopathic Pulmonary Fibrosis
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 175
- 主要终点
- The change from baseline in forced vital capacity (FVC) at week 12
研究概览
简要总结
This study is open to adults with idiopathic pulmonary fibrosis who are at least 40 years old. The main objective is to evaluate of the efficacy and the secondary objective is to evaluate the safety and pharmacokinetic.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •1. Diagnosed with Idiopathic Pulmonary Fibrosis (IPF) prior to screening, patients must meet both of the following criteria:
- •IPF based on 2022 ATS/ERS/JRS/ALAT Guideline as confirmed by the investigator based on chest HRCT scan taken before or during screening period and if available surgical lung biopsy.
- •Usual interstitial pneumonia (UIP) or probable UIP HRCT pattern consistent with the clinical diagnosis of IPF, as confirmed by the investigator prior to screening. if indeterminate HRCT finding IPF may be confirmed locally by (historical) biopsy.
- •2. Percentage Predicted Forced Vital Capacity (ppFVC) ≥45% at screening period.
- •Diffusion capacity of the lung for carbon monoxide (DLCO) (corrected for haemoglobin [Hb]) ≥ 25% and<90% of predicted normal at screening period.
- •4. Patients have to be either:
- •not on therapy with nintedanib or pirfenidone for at least 8 weeks prior to screening and during the screening period, and not planning to start or restart anti fibrotic therapy.
- •on stable therapy with nintedanib or pirfenidone or nerandomilast for at least 12 weeks prior to screening and during the screening period.
排除标准
- •Clinically significant airways obstruction (Forced Expiratory Volume in One Second (FEV1)/Forced Vital Capacity (FVC) < 0.7) at screening.
- •In the opinion of the Investigator, other clinically significant pulmonary abnormalities.
- •Acute IPF exacerbation within 3 months prior to screening and/or during the screening period (investigator-determined).
- •History of persistent or active micturition/defecation syncope, known prior history of syncope, or concomitant other diseases increasing the risk of syncope (e.g., symptomatic bradycardia, second- or third-degree atrioventricular block, symptomatic valvular heart disease, etc.).
- •Major surgery (major according to the investigator's assessment) performed within 3 months prior to screening or planned during the course of the trial. (Being on a transplant list is allowed).
- •Uncontrolled hypertension at screening or prior to randomization/investigational product administration (defined as refractory hypertension as assessed by the investigator, systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg); or hypotension (seated systolic blood pressure <100 mmHg or diastolic blood pressure <60 mmHg).
- •Administration of systemic corticosteroids equivalent to >15 mg prednisone per day within 4 weeks prior to screening and/or during the screening period.
结局指标
主要结局
The change from baseline in forced vital capacity (FVC) at week 12
时间窗: week 12
FVC is a standard pulmonary function test used to quantify respiratory muscle weakness
次要结局
- The change from baseline in forced vital capacity (FVC) at week 26(week 26)
- The change from baseline in percentage predicted forced vital capacity ( ppFVC) at week 12/26(week12/26)
研究者
相似试验
招募中
3 期
Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)NCT07284602PureTech1,100
尚未招募
3 期
FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease ProgressionInterstitial Lung DiseasesNCT07540988Boehringer Ingelheim466
尚未招募
Phase 3 4
To assess the prediction of drug response of enhanced immunosuppressives versus antifibrotics among patients with Progressive Pulmonary Fibrosis (PPF) - RUNNER TrialCTRI/2026/01/100091Indian Council of Medical Research252
终止
2 期
A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary FibrosisProgressive Pulmonary FibrosisIdiopathic Pulmonary FibrosisNCT06360094Boehringer Ingelheim85
进行中（未招募）
不适用
IPF Longitudinal Natural History StudyIdiopathic Pulmonary Fibrosis (IPF)NCT07560189Assiut University1,423